Eric Michael Przybyszewski, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hemangiosarcoma | 1 | 2020 | 239 | 0.630 |
Why?
|
| Liver Diseases, Alcoholic | 3 | 2023 | 161 | 0.570 |
Why?
|
| Living Donors | 2 | 2018 | 620 | 0.570 |
Why?
|
| Liver Transplantation | 4 | 2023 | 2119 | 0.560 |
Why?
|
| Liver Neoplasms | 2 | 2023 | 4253 | 0.550 |
Why?
|
| Rectum | 1 | 2020 | 904 | 0.530 |
Why?
|
| Hepatitis C, Chronic | 1 | 2023 | 1031 | 0.510 |
Why?
|
| Hepatitis C | 1 | 2023 | 1591 | 0.450 |
Why?
|
| Gastrointestinal Hemorrhage | 1 | 2020 | 1130 | 0.440 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2023 | 2214 | 0.390 |
Why?
|
| Pennisetum | 2 | 2021 | 3 | 0.340 |
Why?
|
| End Stage Liver Disease | 2 | 2023 | 314 | 0.340 |
Why?
|
| Graft Survival | 2 | 2018 | 3737 | 0.320 |
Why?
|
| Immunosuppressive Agents | 1 | 2018 | 4149 | 0.260 |
Why?
|
| Graft Rejection | 1 | 2018 | 4397 | 0.250 |
Why?
|
| Hepatorenal Syndrome | 1 | 2023 | 61 | 0.220 |
Why?
|
| Iron | 2 | 2021 | 1774 | 0.210 |
Why?
|
| Alcoholism | 2 | 2023 | 1906 | 0.210 |
Why?
|
| Hepatitis, Alcoholic | 1 | 2023 | 103 | 0.200 |
Why?
|
| Ascites | 1 | 2023 | 344 | 0.190 |
Why?
|
| Cholangitis, Sclerosing | 1 | 2021 | 159 | 0.180 |
Why?
|
| Liver Cirrhosis | 3 | 2024 | 1863 | 0.170 |
Why?
|
| Food, Fortified | 2 | 2021 | 191 | 0.160 |
Why?
|
| Fatty Liver | 1 | 2024 | 727 | 0.160 |
Why?
|
| Physical Exertion | 1 | 2020 | 695 | 0.150 |
Why?
|
| Efficiency | 1 | 2020 | 462 | 0.150 |
Why?
|
| Histocompatibility | 1 | 2018 | 330 | 0.150 |
Why?
|
| Bile Duct Neoplasms | 1 | 2021 | 567 | 0.140 |
Why?
|
| Cholangiocarcinoma | 1 | 2021 | 516 | 0.140 |
Why?
|
| Hepacivirus | 1 | 2023 | 1379 | 0.140 |
Why?
|
| Natural Language Processing | 1 | 2024 | 1041 | 0.130 |
Why?
|
| Fathers | 1 | 2018 | 358 | 0.130 |
Why?
|
| Lymphoproliferative Disorders | 1 | 2018 | 523 | 0.120 |
Why?
|
| Iron, Dietary | 1 | 2015 | 141 | 0.120 |
Why?
|
| Biopsy | 2 | 2024 | 6756 | 0.110 |
Why?
|
| Antiviral Agents | 1 | 2023 | 2987 | 0.100 |
Why?
|
| Acute Kidney Injury | 1 | 2023 | 1972 | 0.090 |
Why?
|
| Proteomics | 1 | 2023 | 3638 | 0.090 |
Why?
|
| Energy Metabolism | 1 | 2020 | 2899 | 0.080 |
Why?
|
| Mothers | 1 | 2018 | 2165 | 0.080 |
Why?
|
| Tissue Donors | 1 | 2016 | 2240 | 0.070 |
Why?
|
| Liver | 1 | 2020 | 7474 | 0.060 |
Why?
|
| Anemia, Iron-Deficiency | 2 | 2020 | 365 | 0.060 |
Why?
|
| Retrospective Studies | 5 | 2023 | 77449 | 0.050 |
Why?
|
| Humans | 14 | 2024 | 744343 | 0.050 |
Why?
|
| India | 2 | 2020 | 2197 | 0.050 |
Why?
|
| Age Factors | 1 | 2018 | 18370 | 0.050 |
Why?
|
| Bile Ducts, Intrahepatic | 1 | 2021 | 295 | 0.050 |
Why?
|
| Alcohol Drinking | 2 | 2023 | 3966 | 0.050 |
Why?
|
| Nutritional Status | 2 | 2020 | 1609 | 0.040 |
Why?
|
| Necrosis | 1 | 2023 | 1643 | 0.040 |
Why?
|
| Male | 7 | 2023 | 350118 | 0.040 |
Why?
|
| Tea | 1 | 2020 | 275 | 0.040 |
Why?
|
| Middle Aged | 6 | 2023 | 213383 | 0.040 |
Why?
|
| Adolescent | 4 | 2021 | 85781 | 0.040 |
Why?
|
| Constriction, Pathologic | 1 | 2021 | 1107 | 0.040 |
Why?
|
| Occupations | 1 | 2020 | 517 | 0.040 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2020 | 20129 | 0.040 |
Why?
|
| Fibroblast Growth Factors | 1 | 2023 | 879 | 0.040 |
Why?
|
| Treatment Outcome | 3 | 2018 | 63114 | 0.040 |
Why?
|
| Ethanol | 1 | 2023 | 1342 | 0.040 |
Why?
|
| Time Factors | 1 | 2018 | 40075 | 0.030 |
Why?
|
| Infant | 1 | 2018 | 35136 | 0.030 |
Why?
|
| Child | 3 | 2021 | 77709 | 0.030 |
Why?
|
| Orosomucoid | 1 | 2015 | 45 | 0.030 |
Why?
|
| Child, Preschool | 1 | 2018 | 41006 | 0.030 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2021 | 2649 | 0.030 |
Why?
|
| Incidence | 2 | 2023 | 20947 | 0.030 |
Why?
|
| Donor Selection | 1 | 2016 | 201 | 0.030 |
Why?
|
| Female | 7 | 2023 | 380194 | 0.030 |
Why?
|
| Receptors, Transferrin | 1 | 2015 | 296 | 0.030 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2020 | 35421 | 0.030 |
Why?
|
| Psychotherapy | 1 | 2022 | 1643 | 0.030 |
Why?
|
| Hepatectomy | 1 | 2016 | 550 | 0.030 |
Why?
|
| Ferritins | 1 | 2015 | 590 | 0.030 |
Why?
|
| Organ Size | 1 | 2016 | 2252 | 0.020 |
Why?
|
| Risk Factors | 1 | 2018 | 72290 | 0.020 |
Why?
|
| Prospective Studies | 3 | 2021 | 53288 | 0.020 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2021 | 3597 | 0.020 |
Why?
|
| Hemoglobins | 1 | 2015 | 1534 | 0.020 |
Why?
|
| Postoperative Complications | 2 | 2023 | 15295 | 0.020 |
Why?
|
| Severity of Illness Index | 1 | 2023 | 15540 | 0.020 |
Why?
|
| Linear Models | 1 | 2015 | 5952 | 0.020 |
Why?
|
| Exercise | 1 | 2021 | 5615 | 0.020 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2020 | 9959 | 0.010 |
Why?
|
| Algorithms | 1 | 2024 | 13881 | 0.010 |
Why?
|
| C-Reactive Protein | 1 | 2015 | 3778 | 0.010 |
Why?
|
| Double-Blind Method | 1 | 2015 | 12026 | 0.010 |
Why?
|
| Aged | 2 | 2023 | 163280 | 0.010 |
Why?
|
| Cohort Studies | 1 | 2023 | 40561 | 0.010 |
Why?
|
| Cross-Sectional Studies | 1 | 2020 | 25043 | 0.010 |
Why?
|
| Adult | 2 | 2023 | 214055 | 0.010 |
Why?
|
| Young Adult | 1 | 2020 | 56430 | 0.010 |
Why?
|
| Follow-Up Studies | 1 | 2015 | 39050 | 0.010 |
Why?
|